

**TABLE 4a.** Demographic and Clinical Characteristic Associated with Long-Term<sup>a</sup> Modified Rankin Scale Outcomes

	No Symptoms Indicated per Modified Rankin Scale		Symptoms Indicated per Modified Rankin Scale		<i>p</i> -value
	No.	%	No.	%	
Total, <i>n</i>	73 <sup>b</sup>		70 <sup>b</sup>		
Recruit status					0.077
No	61	83.6	66	94.3	
Yes	12	16.4	4	5.7	
Antecedent event					0.182
Illness	33	45.2	41	58.6	
Immunization	9	12.3	9	12.9	
Both	24	32.9	12	17.1	
Neither	7	9.59	8	11.4	
Pain present, acute phase					0.021
No	26	35.6	12	17.1	
Yes	47	64.4	58	82.9	
Neuropathic pain treatment					<0.001
No	57	78.1	23	32.9	
Yes	16	21.9	47	67.1	
Modified Rankin Scale nadir, acute phase					0.027
>3	24	32.9	38	54.3	
0–1	21	28.8	13	18.5	
2	28	38.4	19	27.1	
Chronic pain diagnosis					<0.001
No	72	98.6	31	44.3	
Yes	1	1.39	39	55.7	
Results of electrodiagnostic testing <sup>c</sup>					<0.001
Total, <i>n</i>	33 <sup>c</sup>		41 <sup>c</sup>		
Demyelinating	21	63.6	18	43.9	
Axonal, mixed	1	3.0	18	43.9	
Normal	11	33.3	5	12.2	

Abbreviations: MRS, Modified Rankin Scale; *n*, number; No., number; CIDP, chronic inflammatory demyelinating polyneuropathy; FND, functional neurologic disorder.

<sup>a</sup> Greater than 1 year.

<sup>b</sup> Long-term follow-up cases, excluding those with other diagnoses: CIDP, FND, other neurological diagnosis.

<sup>c</sup> Long-term follow-up cases with electro-diagnostic testing results, excluding cases with other diagnoses: CIDP, FND, other neurological diagnosis.